{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:38:09Z","timestamp":1790800689045,"version":"4.1.0"},"reference-count":24,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"unspecified","delay-in-days":85,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2026,3,5]]},"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      The proportion of patients with giant cell arteritis (GCA)-related large vessel vasculitis (LVV) treated with tocilizumab (TCZ) who achieve a complete metabolic response on repeated 18 F-fluorodeoxyglucose positron emission tomography (\n                      <jats:sup>18<\/jats:sup>\n                      FDG-PET)-CT (PET\/CT) is unknown.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective multicentre study that enrolled patients with GCA-related LVV demonstrated on PET\/CT, who were treated with TCZ and underwent at least one repeated PET\/CT. The primary endpoint was the proportion of patients with vascular extinction on repeated PET\/CT during or after TCZ treatment (grade 0 or 1 on the visual vascular to liver FDG uptake grading scale).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 91 patients (64\u2009women (70%), median age: 69 (54\u201383) years) were included. Clinical remission and a complete metabolic response on PET\/CT were observed in 69 patients (76%). Among these, 30 had discontinued all GCA treatments and had not relapsed after &gt;12 months of follow-up post negative PET\/CT; the remaining 39 patients were still treated or had &lt;12 months of follow-up after the negative PET\/CT.<\/jats:p>\n                    <jats:p>13 (14%) patients experienced a relapse of LVV on a third PET\/CT within 12 months after TCZ discontinuation. During follow-up, an aortic dilation occurred in one (1%) patient with complete metabolic extinction and in four (18%) patients who did not show complete and persisting PET\/CT extinction (p=0.006 by log-rank test).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study suggests that TCZ is an interesting therapeutic option for achieving complete metabolic response on PET\/CT in patients with GCA-related LVV. The subsequent risk of aortic dilation may be reduced.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/rmdopen-2025-006563","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T15:50:20Z","timestamp":1774626620000},"page":"e006563","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Complete PET\/CT extinction and subsequent risk of aortic dilation in patients with giant cell arteritis-related large vessel vasculitis treated with tocilizumab"],"prefix":"10.1136","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1105-7662","authenticated-orcid":false,"given":"Ana\u00ebl","family":"Dumont","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Caen University Hospital, Avenue de la C\u00f4te de Nacre, Caen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0821-9990","authenticated-orcid":false,"given":"Olivier","family":"Espitia","sequence":"additional","affiliation":[{"name":"Nantes Universit\u00e9, CHU Nantes, CNRS UMR 6291, INSERM UMR 1087, l\u2019institut du thorax Team III Vascular and Pulmonary Diseases, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime","family":"Samson","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Clinical Immunology, Referral Center for Rare Systemic Autoimmune and Autoinflammatory Diseases, Dijon-Bourgogne University Hospital, University EPE Bourgogne Europe, Dijon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0272-4633","authenticated-orcid":false,"given":"Chlo\u00e9","family":"Comarmond-Ortoli","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, D\u00e9partement M\u00e9dico-Universitaire INVICTUS, Lariboisi\u00e8re Hospital, Assistance Publique-H\u00f4pitaux de Paris (APHP), Nord-Universit\u00e9 Paris Cit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Sailler","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Toulouse University Hospital, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Berthoux","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Saint-Joseph and Saint-Luc Hospital, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fran\u00e7ois","family":"Alexandra","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, H\u00f4pital Bichat, Universit\u00e9 Paris Cit\u00e9, Assistance Publique H\u00f4pitaux de Paris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2842-6695","authenticated-orcid":false,"given":"Marie","family":"Morard","sequence":"additional","affiliation":[{"name":"Nantes Universit\u00e9, CHU Nantes, CNRS UMR 6291, INSERM UMR 1087, l\u2019institut du thorax Team III Vascular and Pulmonary Diseases, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Gallou","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Caen University Hospital, Avenue de la C\u00f4te de Nacre, Caen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00e9mi","family":"Philip","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Caen University Hospital, Avenue de la C\u00f4te de Nacre, Caen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Martin-Silva","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Caen University Hospital, Avenue de la C\u00f4te de Nacre, Caen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gw\u00e9nola","family":"Maign\u00e9","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Caen University Hospital, Avenue de la C\u00f4te de Nacre, Caen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Boutemy","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Caen University Hospital, Avenue de la C\u00f4te de Nacre, Caen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Delacotte","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Caen University Hospital, Avenue de la C\u00f4te de Nacre, Caen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Deshayes","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Caen University Hospital, Avenue de la C\u00f4te de Nacre, Caen, France"},{"name":"UNICAEN, UR4650 PSIR, CHU de Caen Normandie, Normandie Universit\u00e9, Caen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achille","family":"Aouba","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Caen University Hospital, Avenue de la C\u00f4te de Nacre, Caen, France"},{"name":"UNICAEN, UR4650 PSIR, CHU de Caen Normandie, Normandie Universit\u00e9, Caen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert","family":"de Boysson","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Caen University Hospital, Avenue de la C\u00f4te de Nacre, Caen, France"},{"name":"UNICAEN, UR4650 PSIR, CHU de Caen Normandie, Normandie Universit\u00e9, Caen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,3,27]]},"reference":[{"key":"2026032708501184000_12.1.e006563.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61077-6"},{"key":"2026032708501184000_12.1.e006563.2","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.autrev.2017.11.029","article-title":"Large-vessel involvement and aortic dilation in giant-cell arteritis: a multicenter study of 549 patients","volume":"17","author":"de Boysson","year":"2018","journal-title":"Autoimmun Rev"},{"key":"2026032708501184000_12.1.e006563.3","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-018-3973-8"},{"key":"2026032708501184000_12.1.e006563.4","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11041005","article-title":"An updated review of cardiovascular events in giant cell arteritis","volume":"11","author":"de Boysson","year":"2022","journal-title":"J Clin Med"},{"key":"2026032708501184000_12.1.e006563.5","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.7326\/M23-0679","article-title":"Association between vascular 18F-fluorodeoxyglucose uptake at diagnosis and change in aortic dimensions in giant cell arteritis: a cohort study","volume":"176","author":"Moreel","year":"2023","journal-title":"Ann Intern Med"},{"key":"2026032708501184000_12.1.e006563.6","doi-asserted-by":"crossref","unstructured":"Blockmans D , Moreel L , Betrains A , et al . n.d. Association between vascular FDG uptake during follow-up and the development of thoracic aortic aneurysms in giant cell arteritis. Front Med 11:1384533. doi:10.3389\/fmed.2024.1384533","DOI":"10.3389\/fmed.2024.1384533"},{"key":"2026032708501184000_12.1.e006563.7","doi-asserted-by":"crossref","first-page":"103411","DOI":"10.1016\/j.autrev.2023.103411","article-title":"Persistent aortic inflammation in patients with giant cell arteritis","volume":"22","author":"Kaymakci","year":"2023","journal-title":"Autoimmun Rev"},{"key":"2026032708501184000_12.1.e006563.8","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/art.40379","article-title":"18F-fluorodeoxyglucose positron emission tomography as an imaging biomarker in a prospective, longitudinal cohort of patients with large vessel vasculitis","volume":"70","author":"Grayson","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"2026032708501184000_12.1.e006563.9","doi-asserted-by":"crossref","first-page":"3851","DOI":"10.1093\/rheumatology\/keab332","article-title":"Resolution of vascular inflammation in patients with new-onset giant cell arteritis: data from the RIGA study","volume":"60","author":"Sch\u00f6nau","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"2026032708501184000_12.1.e006563.10","doi-asserted-by":"crossref","DOI":"10.1093\/rap\/rkaa017","article-title":"Long-term treatment with tocilizumab in giant cell arteritis: efficacy and safety in a monocentric cohort of patients","volume":"4","author":"Regola","year":"2020","journal-title":"Rheumatol Adv Pract"},{"key":"2026032708501184000_12.1.e006563.11","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2020-001417","article-title":"Efficacy and safety of tocilizumab in giant cell arteritis: a single centre NHS experience using imaging (ultrasound and PET-CT) as a diagnostic and monitoring tool","volume":"6","author":"Sebastian","year":"2020","journal-title":"RMD Open"},{"key":"2026032708501184000_12.1.e006563.12","doi-asserted-by":"crossref","first-page":"152174","DOI":"10.1016\/j.semarthrit.2023.152174","article-title":"Effectiveness of a two-year tapered course of tocilizumab in patients with giant cell arteritis: A single-centre prospective study","volume":"59","author":"Tomelleri","year":"2023","journal-title":"Semin Arthritis Rheum"},{"key":"2026032708501184000_12.1.e006563.13","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead215"},{"key":"2026032708501184000_12.1.e006563.14","doi-asserted-by":"crossref","first-page":"3057","DOI":"10.1093\/rheumatology\/keae400","article-title":"Treatment of giant cell arteritis with ultra-short glucocorticoids and tocilizumab: results from the extension of the TOPAZIO study","volume":"64","author":"Muratore","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"2026032708501184000_12.1.e006563.15","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.181222"},{"key":"2026032708501184000_12.1.e006563.16","doi-asserted-by":"crossref","first-page":"4384","DOI":"10.1093\/rheumatology\/keaa894","article-title":"Use of 18F-fluorodeoxyglucose positron emission tomography to monitor tocilizumab effect on vascular inflammation in giant cell arteritis","volume":"60","author":"Quinn","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"2026032708501184000_12.1.e006563.17","doi-asserted-by":"crossref","DOI":"10.1002\/acr2.11797","article-title":"Use of 18F-fluorodeoxyglucose positron emission tomography to monitor disease activity in patients with giant cell arteritis on tocilizumab","volume":"7","author":"Quinn","year":"2025","journal-title":"ACR Open Rheumatol"},{"key":"2026032708501184000_12.1.e006563.18","doi-asserted-by":"crossref","first-page":"69","DOI":"10.55563\/clinexprheumatol\/mjm8fr","article-title":"Evidence for uncoupling of clinical and 18-FDG activity of PET\/CT scan improvement in tocilizumab-treated patients with large-vessel giant cell arteritis","volume":"39 Suppl 129","author":"Prieto Pe\u00f1a","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"2026032708501184000_12.1.e006563.19","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ejim.2024.06.013","article-title":"Effectiveness of tocilizumab in aortitis and aneurysms associated with giant cell arteritis","volume":"129","author":"Mart\u00edn-Guti\u00e9rrez","year":"2024","journal-title":"Eur J Intern Med"},{"key":"2026032708501184000_12.1.e006563.20","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1002\/art.42325","article-title":"2022 American College of Rheumatology\/EULAR classification criteria for giant cell arteritis","volume":"74","author":"Ponte","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"2026032708501184000_12.1.e006563.21","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224543"},{"key":"2026032708501184000_12.1.e006563.22","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ejim.2024.03.038","article-title":"Evolution and outcomes of aortic dilations in giant cell arteritis","volume":"129","author":"Gallou","year":"2024","journal-title":"Eur J Intern Med"},{"key":"2026032708501184000_12.1.e006563.23","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1002\/art.41774","article-title":"2021 American College of Rheumatology\/Vasculitis Foundation guideline for the management of giant cell arteritis and Takayasu arteritis","volume":"73","author":"Maz","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2026032708501184000_12.1.e006563.24","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.revmed.2024.10.011","article-title":"French protocol for the diagnosis and management of giant cell arteritis","volume":"46","author":"de Boysson","year":"2025","journal-title":"Rev Med Interne"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2025-006563","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T15:50:23Z","timestamp":1774626623000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2025-006563"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,3,27]]},"published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1136\/rmdopen-2025-006563"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2025-006563","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]}}}